Proactive Investors
21 Sept 2026, 13:42 UTC · 2h ago
Verdict
Headline takes no side. We score COIL +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 70% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 1 new · 3 priced in
Coiled Therapeutics expects preliminary efficacy results for AO-252 in the first half of 2027.
Priced inbroker analysis of timelines
So whatThis creates a valuation catalyst horizon of roughly 6-12 months that could trigger a buyout or licensing deal.
More positive than 92% of claims this week
Coiled Therapeutics has enrolled six patients across two dose groups for a reformulated softgel version of AO-252.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Newreported as Monday's news on Sep 21
So whatThe company aims to scale this to 30 patients by year-end, representing a 5x increase in the current cohort size.
More positive than 62% of claims this week
The company expects initial safety data for the reformulated drug by the end of this year.
Priced inbroker analysis of timelines
So whatA safety failure in Q4 2026 would likely invalidate the H1 2027 efficacy timeline.
More positive than 49% of claims this week
AO-252 has previously demonstrated an 80% clinical benefit rate in a small group of heavily pre-treated patients.
Priced inreference to existing drug data
More positive than 40% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
Positive progress in cancer drug trials with analyst support and the enrollment of patients for a reformulated drug.
More positive than 58% of ticker scores this week
Positive news regarding the signing of a deal to build at least 10,000 units.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
5h ago
—
No price for COIL right now — the quote feed didn't answer.
COIL chart →
